Edition:
United States

ProQR Therapeutics NV (PRQR.A)

PRQR.A on American Stock Exchange

12.03USD
3:38pm EDT
Change (% chg)

$0.43 (+3.71%)
Prev Close
$11.60
Open
$12.05
Day's High
$12.05
Day's Low
$12.03
Volume
400
Avg. Vol
369
52-wk High
$23.99
52-wk Low
$5.15

Summary

Name Age Since Current Position

Daniel De Boer

32 2012 Founding Chief Executive Officer

Gerard Platenburg

50 Co-Founder, Chief Innovation Officer

Smital Shah

2018 Chief Business and Financial Officer

Lisa Hayes

2018 Vice President - Investor Relations and Corporate Communications

Tiffany Burt

2018 Vice President, Head - Commercial

Aniz Girach

2018 Chief Medical Officer

David Rodman

2017 Chief Development Strategy Officer

Biographies

Name Description

Daniel De Boer

Mr. Daniel De Boer serves as Founding Chief Executive Officer of ProQR Therapeutics NV. He has been a serial entrepreneur in IT who has led a number of other companies through phases of growth, initiating development and launch of several IT related products in several European countries. Prior to founding ProQR, Daniel served as a founder and Chief Executive Officer of RNA Systems, founder and Chief Executive Officer of PC Basic, and founder and Chief Executive Officer of Running IT. Daniel is responsible for the overall strategy and general business in the company.

Gerard Platenburg

Mr. Gerard Platenburg is a Co-Founder, Chief Innovation Officer of ProQR Therapeutics NV. He served as the sole Member of the Company's Supervisory Board between August 2012 and December 2013. He has more than twenty years of senior managerial experience, which he gained during his different operational and leadership roles in growing biotech companies. Prior to joining the Company, Mr. Platenburg worked at Isa Pharmaceuticals B.V. from June 2009 to January 2014. Mr. Platenburg co-founded Prosensa Holding N.V., growing it to become a well-known RNA modulation clinical stage company, and held various positions between April 2002 and May 2009, including Chief Executive Officer and Chief Development Officer. Mr. Platenburg also worked at Pharming B.V. from April 1990 to March 2002. He is a passionate and driven pioneer of early stage technologies. Mr. Platenburg has a master degree in chemistry and molecular biology from Leiden University in 1987 and pursued PhD work at Leiden University.

Smital Shah

Ms. Smital Shah serves as Chief Business and Financial Officer of ProQR Therapeutics NV, since October 2014. She has a 12-year track record of management and leadership in biopharma companies and investment banking, with particular experience in financial strategy and capital markets. Prior to joining the Company she was at Gilead Sciences, where she managed their multi-billion dollar debt, cash and investment portfolios. Prior to Gilead, she spent several years in investment banking at Leerink Partners and JP Morgan focused on capital raising and strategic transactions in the biotech space. Previously, she held various R&D focused roles at Johnson & Johnson. Ms. Smital Shah has a Bachelors and Masters in Chemical Engineering and an MBA from the University of California at Berkeley.

Lisa Hayes

Ms. Lisa A. Hayes serves as Vice President - Investor Relations and Corporate Communications of the Company. Lisa A. Hayes will join ProQR as Vice President of Investor Relations and Corporate Communications and brings over 20 years of experience in the healthcare space. Lisa joins ProQR from Celgene, where she was most recently Senior Director of Investor Relations. She also has an extensive background in competitive intelligence with experience at Celgene, J&J and Sanofi (formerly Aventis).

Tiffany Burt

Ms. Tiffany Burt serves as Vice President, Head - Commercial of the Company. Tiffany Burt has more than 20 years of global commercial experience spanning across all phases of pre-launch market development and global biopharmaceutical commercialization including multiple rare therapeutic areas. She has been involved with the launch of 8 different products. Prior to joining ProQR, she served as Vice President, Marketing at Verastem Oncology where she built the marketing organization including key platforms and programs across the commercial organization launching Duvelisib in 2018. Before joining Verastem, Tiffany held numerous commercial leadership positions at EMD Serono, ARIAD and Novartis.

Aniz Girach

Mr. Aniz Girach, M.D., serves as Chief Medical Officer of the Company. Aniz is an experienced ophthalmologist and has over 20 years of experience in the biotech industry focusing on retinal diseases. He has been involved with the development and approval of four drugs Jetrea (ocriplasmin) being the latest one. Most recently, Aniz worked as the Chief Medical Officer for Nightstar Therapeutics where he oversaw the development of gene therapies for inherited retinal disorders. Previously, he was the Global Head of Ophthalmology at Thrombogenics (now Oxurion), VP of International Clinical Development at Alcon and Executive Medical Director and Global Head of Ophthalmology at Merck.

David Rodman

Dr. David M. Rodman M.D., is Chief Development Strategy Officer of the Company. Dr. Rodman joined ProQR in March 2017 with extensive experience in rare disease drug development, translational medicine and RNA therapeutics, having previously served in leadership roles with Novartis Institute for Biomedical Research (NIBR), Vertex Pharmaceuticals, miRagen Therapeutics and Nivalis Therapeutics.

Basic Compensation

Options Compensation